Massive study tracks Real-World breast cancer care in china
NCT ID NCT07476170
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how patients with HR+/HER2- advanced or metastatic breast cancer are actually treated in China, and how well those treatments work. Researchers will analyze data from 14,000 patients to see which first-line therapies are used, how often patients switch treatments, and how long they stay on each therapy. The goal is to fill gaps in knowledge about real-world outcomes, especially for newer drugs like ribociclib.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative SIte
RECRUITINGBingjie, Beijing Municipality, 100021, China